BioSpace News Archive

Biotech Bay

Arcus Biosciences Announces New Employment Inducement Grants - July 12, 2021

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 77,800 shares of the Company’s common stock at an exercise price per share of $28.75, which was the closing price on July 8, 2021.

July 12, 2021
·
2 min read
Business

PPD Announces Second Quarter 2021 Earnings Conference Call

PPD, Inc. will host a conference call on Thursday, July 29, 2021, at 7 a.m. (U.S. Eastern Time) to discuss its second quarter 2021 financial results.

July 12, 2021
·
1 min read
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China

--This bridging study to select doses for the Phase II trial in China in patients with chronic hepatitis B (CHB) --ASC42 clinical trials are being conducted in the U.S. and China for non-alcoholic steatohepatitis (NASH) and CHB.

July 12, 2021
·
4 min read
Pharm Country

IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions

July 12, 2021
·
5 min read
BioCapital

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19

AditxtScore™ for COVID-19 Now Includes Virus-Specific Infection Blocking Antibodies that Assess the Strength of an Individual’s Immune Response to SARS-CoV-2

July 12, 2021
·
4 min read
BioMidwest

Aptinyx to Participate in William Blair Biotech Focus Conference 2021

Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET.

July 12, 2021
·
1 min read
Drug Development

Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus

Regulatory News: Aptorum Group Limited announces further positive results of its ongoing Phase 1 clinical trial for ALS-4 (a first in-class anti-virulence approach based small molecule targeting.

July 12, 2021
·
5 min read
Pharm Country

Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

Brooklyn ImmunoTherapeutics LLC today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13-15, 2021.

July 12, 2021
·
1 min read
Business

nference and Mayo Clinic Study Confirms Link Between Anemia and Rehospitalization After COVID-19 Infection Clearance

nference today announced publication of a study in iScience that analyzed Mayo Clinic data with nference artificial intelligence (AI) software to suggest that anemia-related laboratory tests should be considered in risk stratification algorithms for COVID-19 patients.

July 12, 2021
·
2 min read
FDA

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO.

July 12, 2021
·
4 min read